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The process of assessing the health risks asso-
ciated with human exposure to toxic environ-
mental chemicals inevitably relies on a
number of assumptions, estimates, and
rationalizations. Some of the greatest chal-
lenges result from the necessity to extrapolate
from the conditions in the studies providing
evidence of the toxicity of the chemical to the
anticipated conditions of exposure in the
environment or workplace. For risk assess-
ments based on animal data, the most obvi-
ous extrapolation that must be performed is
from the tested animal species to humans;
however, others are also generally required:
from high dose to low dose, from one expo-
sure route to another, and from one exposure
time frame to another. Physiologically based
pharmacokinetic (PBPK) modeling provides a
powerful method for increasing the reliability
of these extrapolations (1–3). The inherent
capabilities of PBPK modeling are particularly
advantageous for cross-species extrapolation:
the physiological and biochemical parameters
in the model can be changed from those for
the test species to those that are appropriate
for humans to provide a biologically mean-
ingful animal-to-human extrapolation.
However, it is important to recognize that a
full PBPK model may not always be necessary
to support a pharmacokinetic risk assessment.
In some cases only a simple compartmental
pharmacokinetic description is needed; an
excellent example has been published for the
case of cadmium (4–5). 
Simple pharmacokinetic approaches have
occasionally been used by regulatory agencies
in cancer risk assessment; for example, the
use of metabolized dose for trichloroethylene
(6,7). The ﬁrst case in which an agency has
used a full PBPK approach was in the U.S.
Environmental Protection Agency’s (U.S.
EPA) latest revision of its inhalation risk
assessment for methylene chloride (8). The
decision to use the PBPK approach in this
case was made only after a period of consid-
erable controversy, including a workshop
sponsored by the National Academy of
Sciences at which the usefulness of PBPK
modeling for chemical risk assessment was
discussed. The scientiﬁc consensus following
the workshop was that “relevant PBPK data
can be used to reduce uncertainty in extrap-
olation and risk assessment”(9). In 1989,
after a detailed multiagency evaluation of the
available PBPK information and a review by
the U.S. EPA Scientiﬁc Advisory Board, the
U.S. EPA revised the inhalation unit risk
and risk-speciﬁc air concentrations for meth-
ylene chloride in its Integrated Risk
Information System (IRIS) database, citing
the PBPK model developed by Andersen et
al. (10). The resulting risk estimates were
lower than those obtained by the default
approach by nearly a factor of 10. This dif-
ference was driven by the lower rate of
metabolism in humans compared to mice,
giving rise to the reactive intermediate asso-
ciated with the tumors. Subsequently, an
adaptation of the same PBPK model was
used by the Occupational Safety and Health
Administration (OSHA) in making rules for
methylene chloride (11). More recently, the
U.S. EPA has used PBPK models for vinyl
chloride (12) and 2-butoxyethanol (13) in its
risk assessments for these chemicals.
The advantages of applying PBPK model-
ing in risk assessment have been discussed
both for cancer (9,14–17) and noncancer end
points (18–21). In addition, the use of PBPK
modeling has been recommended to improve
route-to-route extrapolation (22) and the esti-
mation of risk for chemical mixtures (23).
Recently, there has been an increasing focus
on harmonization of the cancer and non-
cancer risk assessment paradigms used by reg-
ulatory agencies in the United States. 
The specific details of applying PBPK
modeling within these two paradigms may
differ. For example, lifetime average daily
dose is used for cancer risk assessment,
whereas average daily dose during exposure is
used for noncancer. Nevertheless, it is possi-
ble to identify important elements common
to both (24). The starting point for a harmo-
nized approach is a four-part framework for
organizing qualitative and quantitative analy-
ses of data available for chemical risk assess-
ment. The four elements are exposure, tissue
dosimetry, toxicity process, and response
(Figure 1). Tissue dosimetry information is
obtained from quantitative pharmacokinetic
analyses. Quantitative descriptions of the
processes leading to toxicity are referred to as
pharmacodynamic analyses. These two ele-
ments link the exposure with the response
and are often described as the mode of action
of a chemical (although it should be noted
that mode of action has also been used syn-
onymously with toxicity process). The four
elements form the basis for analyzing toxicity
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carrying out extrapolations between the
species. They represent the minimum ele-
ments necessary for risk assessment purposes;
elaborated series of steps can also be given
that more completely describe the biological
processes. In the following discussion, we
describe the key elements of the approach for
applying pharmacokinetic modeling of tissue
dosimetry to dose–response assessment in a
format equally applicable to both cancer and
noncancer end points.
Dose Metric Selection
The ultimate aim of using pharmacokinetic
modeling in risk assessment is to provide a
measure of dose that better represents the
“biologically effective dose”; that is, the dose
that causally relates to the toxic outcome.
The improved dose metric can then be used
in place of traditional dose metrics (such as
concentration or exposure dose) in an appro-
priate dose–response model to provide a
more accurate extrapolation to the human
exposure conditions of concern. Implicit in
any application of pharmacokinetics to risk
assessment is the assumption that the toxic
effects can be related to the concentration of
an active form of the substance in the mech-
anistically relevant tissue. Often the tissue in
which the chemical is active is the same tis-
sue in which the toxic effects occur; this is
the target tissue. Sometimes, the target for
the effects of a chemical and the organ in
which the toxicity are observed are different
(e.g., effects on brain may alter hormonal sig-
naling observed as toxicity in a reproductive
organ). In this case, the term “target tissue”
must be used with care because the concept is
altered from its traditional usage. Similar
responses are expected to be produced at
equivalent tissue exposures regardless of
species, exposure route, or experimental regi-
men unless there are pharmacodynamic dif-
ferences between animal species (3,25,26).
The motivation for applying pharmacokinet-
ics in risk assessment is the expectation that
the observed effects of a chemical will be
more simply and directly related to a measure
of target tissue exposure than to a measure of
administered dose (1,27). 
The specific nature of the relationship
between target tissue exposure and response
depends on the chemical mechanism of toxi-
city, or mode of action, involved. Many
short-term, rapidly reversible toxic effects,
such as acute skin irritation or acute neuro-
logic effects, may result primarily from the
current concentration of the chemical in the
tissue. In such cases, the likelihood of toxicity
from a particular exposure scenario can be
conservatively estimated by the maximum
concentration (CMAX) achieved in the target
tissue (28–30). In contrast, the acute toxicity
of highly reactive chemicals, as well as many
longer-term toxic effects such as tissue necro-
sis and cancer, may be cumulative in nature,
depending on both the concentration and
duration of the exposure. A simple metric for
such cases is the area under the concentration
curve (AUC) in the tissue, which is deﬁned
mathematically as the integral of the concen-
tration over time (27,31,32). This mathe-
matical form implicitly assumes that the
effect of the chemical on the tissue is linear
over both concentration and time. The use of
the AUC represents an extension of the con-
cept, developed from observations of the
effects of chemical warfare gases (33), that
toxicity is proportional to the product of the
concentration and time of exposure (C × T).
For developmental effects, the chemical time
course may also have to be viewed in the con-
text of the window of susceptibility for a par-
ticular gestational event (34).
An important factor in selecting an
appropriate dose metric is to determine the
toxicologically active form of the chemical.
In some cases, a chemical may produce a
toxic effect directly, either through its reac-
tion with tissue constituents (e.g., ethylene
oxide) or its binding to cellular control ele-
ments (e.g., dioxin). Often, however, it is
metabolism of the chemical that leads to its
toxicity. In this case, toxicity may result pri-
marily from reactive intermediates produced
during the process of metabolism (e.g.,
chlorovinyl epoxide produced from the
metabolism of vinyl chloride) or from the
toxic effects of stable metabolites (e.g.,
trichloroacetic acid produced from the
metabolism of trichloroethylene). The selec-
tion of the dose metric, that is, the active
chemical form for which tissue exposure
should be determined and the nature of the
measure to be used (e.g., CMAX or AUC) is
the most important step in applying phar-
macokinetics in risk assessment. 
Dose metrics must be selected to be con-
sistent with the modes of action for the chem-
ical being evaluated. No single dose metric
will always be appropriate for a given effect,
although consistency is expected for chemicals
acting via the same mechanism. The U.S.
EPA (35), in a joint effort with scientists from
several other agencies, prepared a review paper
on cross-species extrapolation in cancer risk
assessment which concluded that 
… [T]issues experiencing equal average concen-
trations of the carcinogenic moiety over a full
lifetime should be presumed to have equal life-
time cancer risk.
The use of the term “carcinogenic moiety”
in this statement reﬂects the concern that the
dose metric should be representative of the
active form of the chemical. For example, the
use of the lifetime average daily concentration
for the parent chemical would be appropriate
for a directly genotoxic chemical such as ethyl-
ene oxide, which is detoxiﬁed by metabolism;
however, it would not be appropriate for a
chemical such as vinyl chloride, which requires
metabolic activation to be genotoxic. In the
latter case, increasing metabolism would
increase the exposure to the genotoxic species
but would decrease a dose metric based on the
concentration of the parent chemical. In such
a case, where a reactive species produced dur-
ing the metabolism of a chemical is responsi-
ble for its carcinogenicity, an appropriate
cancer dose metric would be the lifetime aver-
age daily production of metabolite in the tar-
get tissue divided by the volume of the tissue,
as described in the pharmacokinetic risk
assessment for methylene chloride (10).
Similar considerations apply in the case of
noncancer risk assessment, except that the
dose metrics are only averaged over the dura-
tion of the exposure (acute, subchronic, or
chronic) or the critical developmental win-
dow, not over a full lifetime (28).
Finally, it should be noted that although
CMAX and AUC are the most commonly
applied metrics for tissue exposure, other
dose metrics might sometimes be more
appropriate, particularly for chemicals with a
mode of action related to some aspect of their
interaction with a receptor. In such cases,
time above a critical concentration (TACC)
or average receptor occupancy might be more
appropriate (36,37). Unfortunately, the more
we attempt to include pharmacodynamic
processes into a dose metric (e.g., receptor
occupancy), the more difficult it usually
becomes to collect the data necessary for its
use in each of the relevant species. Of the
many possible dose metrics, typically only
CMAX, AUC, and TACC can be estimated
from the kinds of data currently available on
chemicals. Although we have discussed these
dose metrics in terms of the target tissue,
there is often a simple proportional relation-
ship between the blood level and the tissue
level so the dose metrics used are in blood
rather than in tissue. Typically, data on blood
concentrations are more often available, par-
ticularly in humans, making it possible to
validate model predictions.
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Figure 1. Framework for using mode of action













(animal–human)The Ratio Concept in Risk
Assessment
Although it is crucial that the dose metric
properly represents the essential nature of the
biologically effective dose, as described above,
it is often possible to simplify the actual dose
metric calculation by recognizing that quan-
titative risk assessment is fundamentally
based on a ratio, speciﬁcally, the ratio of the
dose metric value for the exposure of concern
to the value for the exposure (or exposures)
deﬁning the toxicity. Typically, the exposures
defining the toxicity might be the no-
observed-adverse-effect level (NOAEL) in an
animal experiment or the doses in a cancer
bioassay, whereas the exposure of concern
might be a lifetime continuous human expo-
sure. Any factors that do not change across
the conditions of these exposures will not
effect the ratio of the dose metrics, and thus
will not impact the risk assessment.
For example, the ultimate dose metric
for a particular toxicity might be based on
the concentration of the chemical in the tar-
get tissue. However, an acceptable dose met-
ric might be based on the chemical’s blood
concentration as long as the relationship
between the blood concentration and target
tissue concentration could be expected to be
the same in both the animal toxicity study
and in human exposure. In fact, this is prob-
ably a reasonable assumption across different
exposure conditions in a given species:
namely, that the concentrations would be
related by the tissue:blood partition coeffi-
cient. However, although tissue:air partition
coefficients for volatile lipophilic chemicals
appear to be similar in dogs, monkeys, and
humans (38), human blood:air partition
coefﬁcients appear to be roughly one-half of
those in rodents (39). Therefore, the human
tissue:blood partition would probably be
about twice that in the rodent. Thus, if the
model was used for extrapolation from
rodents to humans, this 2-fold difference
could be factored into the analysis as an
adjustment to the blood concentration dose
metric.
The dose metric for a reactive metabolite
provides another example of the use of this
ratio concept: the amount of metabolism
divided by the volume of the tissue is used as
a surrogate for the average concentration of
the reactive species, on the assumption that
other factors remain constant. That is, we
assume that the stoichiometric yield of the
reactive species and its reaction rate are
invariant across species and over the expo-
sure conditions being modeled.
Use of the ratio concept can greatly sim-
plify risk assessment applications of pharma-
cokinetic modeling for developmental
toxicity or teratogenicity studies. Although it
may seem necessary to use a model that
includes compartments for the developing
fetus, this may not always be the case. For
some chemicals, the maternal blood or
plasma concentration proﬁle can provide an
adequate surrogate for the fetal exposure
(40,41). An important point is that symmet-
ric diffusion limitation, such as might be
expected for placental transport of many
environmental contaminants, does not affect
the AUC in the tissue. That is, while diffu-
sion-limited transport across the placenta
might delay the achievement of the maxi-
mum concentration in the fetus as compared
to the maternal blood, the AUC in the fetus
would bear the same relationship to the
AUC in the blood as it would in the case of
ﬂow-limited transport. Moreover, for expo-
sures of sufficient duration to reach steady
state, the steady-state fetal concentration will
be completely determined by partitioning
and will not be affected by diffusion-limited
transport. For many chemicals, the only
important pharmacokinetic complication
associated with fetal development is the
resulting increase in the total volume of dis-
tribution for the chemical. This complication
may be ignored for risk assessment purposes
because the effect can be similar in both the
toxicity study and the human exposure of
concern.
Impact of Pharmacokinetics in
Risk Assessment
Pharmacokinetics has been addressed differ-
ently in the default noncancer and cancer
approaches. The standard paradigm for non-
cancer risk assessment rarely considers chem-
ical-specific pharmacokinetic information;
typically, a NOAEL or lowest-observed-
adverse-effect level (LOAEL) derived from
data for the exposure route of interest is sim-
ply adjusted by the application of generic
uncertainty factors (UFs) to obtain reference
concentrations (RfCs) or reference doses
(RfDs). Individual UFs of from 1 to 10 are
applied for various potential sources of
uncertainty including use of a LOAEL,
extrapolation to a longer exposure duration,
extrapolation from animals to humans,
human variability, and database limitations.
Typically the total UF (the product of the
individual UFs) is restricted to a maximum
of 3,000 (42).
In this paradigm, little attention has
been given to incorporating knowledge of
the mode of action or the dosimetry of the
active chemical form in target tissues in these
calculations. The selection of UFs has also
generally failed to consider chemical-speciﬁc
mechanistic information or pharmacokinetic
data. One exception is the focus in the
revised RfC process on delivered dose adjust-
ments for inhaled materials (42).
In the traditional paradigm for cancer risk
assessment in the United States, dose–
response modeling was used to calculate a car-
cinogenic potency based on tumors observed
in animal bioassays or human epidemiology
studies. In the case of animal studies, “body
surface area” scaling (multiplying by the cube
root of the ratio of the animal and human
body weights) was used to obtain a human
equivalent dose (HED) (Table 1, Appendix
1). Dose–response modeling was then per-
formed on the HEDs using the linearized
multistage model (43). For inhalation studies,
conversion from inhaled concentration to
absorbed dose was performed by a rudimen-
tary calculation involving the ventilation rate,
body weight, and fraction absorbed. As men-
tioned above, chemical-speciﬁc pharmacoki-
netic information has occasionally been used
in this process; for example, the calculation of
metabolized dose in the risk assessment for
trichloroethylene (6,7), and the use of a
PBPK model in the risk assessment for
methylene chloride (8). The guidelines for
carcinogen risk assessment recently proposed
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Table 1. Examples of interspecies scaling based on body weight ratios.*
ADD for
species A/H ratio H/A ratio HED
Species BWb (mg/kg/day) (A/H)1–b (H/A)1–b (mg/kg/day)
b = 1 BW1 (A/H)0 (H/A)0
Human 70 1 1 1 1
Rat 0.25 1 1 1 1
Mouse 0.030 1 1 1 1
b = 3/4 BW3/4 (A/H)1/4 (H/A)1/4
Human 24.20 1 1.0 1.0 1
Rat 0.354 1 0.244 4.1 0.244
Mouse 0.0721 1 0.144 7.0 0.144
b = 2/3 BW2/3 (A/H)1/3 (H/A)1/3
Human 16.5 1 1.0 1.0 1
Rat 0.401 1 0.153 6.5 0.153
Mouse 0.0988 1 0.075 13.3 0.075
Abbreviations: ADD, average daily dose; b, scaling exponent; BW, body weight; A, animal body weight; H, human body
weight.
*Representative values of body weight for different species have been assumed; the ADD was assumed to be 1
mg/kg/day. The HED for each animal species’ ADD was calculated using Equation 8 in Appendix 1 and the assumed values
of BW and ADD shown above.by the U.S. EPA (44) would appear to pro-
vide the ﬂexibility necessary to move forward
in this area. Under the new guidelines, multi-
ple options are available for performing a car-
cinogenic dose–response assessment including
a linear approach similar to the traditional
cancer paradigm, and a margin of exposure
(MOE) approach more similar to the non-
cancer paradigm. The selection of the
dose–response approach to be used with a
particular chemical is determined on the basis
of the information available on the carcino-
genic mode of action of the chemical, which
considers both pharmacokinetic and mecha-
nistic information. 
Cross-species extrapolation. In the tradi-
tional default risk assessment approaches, all
chemicals are implicitly treated as if the
observed toxicity is produced directly by the
parent chemical itself (3). This implicit
assumption that the parent chemical is
directly toxic is true even in the new RfC
dosimetry guidelines (42), which differenti-
ate respiratory effects from extra-respiratory
effects and include different defaults for
chemicals based on their solubility and reac-
tivity. However, a risk assessment that con-
siders pharmacokinetics must necessarily also
consider the mode of action, at least to the
extent of identifying the active form of the
chemical for which the dosimetry should be
performed. 
To demonstrate the importance of con-
sidering pharmacokinetics and mode of
action in dose–response risk assessment, we
used PBPK models for methylene chloride
(10), trichloroethylene (21), and vinyl chloride
(12) to determine general expectations for the
cross-species dosimetry for one class of chemi-
cals, the volatile lipophilic solvents. All three of
these chemicals are considered category 3 gases
(relatively water-insoluble chemicals that
achieve a steady state during inhalation expo-
sure) in the U.S. EPA dosimetry guidelines
(42). In a standard risk assessment, the ani-
mal-to-human dosimetry adjustment for each
of these chemicals would be performed in
exactly the same way. For example, for non-
cancer analyses, time-weighted average
(TWA) exposure concentration for inhalation
and milligrams per kilogram per day adminis-
tered dose for oral exposure are used, regard-
less of the nature of the toxic end point or the
mechanism of toxicity.
In contrast to the simplicity and unifor-
mity of the default approaches, a pharmaco-
kinetic approach requires the application of
scientiﬁc judgment to select the appropriate
option for each toxic effect of a chemical.
Table 2 provides a comparison of the default
and PBPK-based approaches as a function of
the type of toxicity and the exposure route
based upon the analyses for methylene chlo-
ride, vinyl chloride, and trichloroethylene.
For the purpose of this comparison, we
assumed that the acute, reversible neurologic
effects of these chemicals result from the
direct toxicity of the parent chemical; thus,
an appropriate dose metric would be either
the CMAX or the AUC of the parent chemi-
cal in the brain or, as discussed above, in the
blood as a surrogate for the brain. For the
calculations used to prepare Table 2, we
selected the AUC because it is more analo-
gous to the TWA calculation typically used
for duration adjustment. In contrast, because
we assumed that the production of reactive
species during metabolism was responsible
for the chronic liver toxicity of methylene
chloride and vinyl chloride, we used the
average daily amount of metabolism divided
by the volume of the liver as the dose metric.
Finally, we assumed that the development of
liver toxicity from trichloroethylene resulted
from the activity of the stable metabolite,
trichloroacetic acid; therefore, we used the
average daily AUC for trichloroacetate in the
liver as the dose metric. 
To obtain the comparisons shown in
Table 2, we used the PBPK models to deter-
mine dose metrics for a typical exposure sce-
nario in the mouse and rat. The models were
then rerun for the same exposure scenario
but with human parameters, and the con-
centration or dose was varied until the
human dose metric was the same as that
obtained for the mouse and rat. These two
pharmacokinetically determined human
equivalent concentrations (HECs) or doses
(HEDs), one for the mouse and one for the
rat, were then compared to the correspond-
ing HECs or HEDs obtained by the default
methodology. No animal-to-human UFs
were applied in this comparison.
As shown in Table 2, the correct relation-
ship for cross-species dosimetry depends on
whether the toxicity is due to the parent
chemical or a metabolite, and in the case of
toxicity from a metabolite, whether the
metabolite is highly reactive or sufﬁciently sta-
ble to enter the circulation. Moreover, the
nature of the cross-species relationship for
each of these possibilities is different for oral
exposure than for inhalation. Therefore, phar-
macokinetic modeling is required to improve
the reliability of cross-species extrapolation
that considers the nature of the toxic entity. 
Default noncancer risk assessments apply
a UF of 10 for uncertainty regarding animal-
to-human extrapolation. This UF is applied
to consider the possibility of both pharmaco-
kinetic and pharmacodynamic differences
between rodents and humans that could put
the human at greater risk (i.e., result in toxic-
ity at lower exposures) and is reduced to 3
when inhalation dosimetry is used to con-
sider pharmacokinetic differences (42). A
reduced factor of 3 has also sometimes been
applied for data from species that are consid-
ered physiologically “closer” to humans, such
as dogs or monkeys. This UF plays the same
role, and is roughly the same magnitude as
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Table 2. Alternative metrics for cross-species equivalence.
Human/animal
Route, basis Metric dose equivalence ratio
Inhalation
Default
1986 U.S. EPA cancer guidance (45) Inhaled dose × (A/H)1/3 0.15–0.3
New U.S. EPA cancer guidance (44) TWA Conc (PD:UF = 1–10) 1
U.S. EPA noncancer guidance (42) TWA Conc (PD:UF = 3) 1
Allometric
Parent chemical TWA Conc 1
Reactive metabolite TWA Conc/(A/H)1/4 4–7
Stable metabolite TWA Conc 1
PBPKa
Parent chemical Parent AUC 0.6–1.7
Reactive metabolite Tmet/Vt 5–25
Stable metabolite Metabolite AUC 0.1–1
Oral
Default
1986 U.S. EPA cancer guidance (45) Dose × (A/H)1/3 0.08–0.16
New U.S. EPA cancer guidance (44) Dose × (A/H)1/4 0.15–0.25
U.S. EPA noncancer guidance (42) Dose (PK+PD:UF = 10) 0.3
Allometric
Parent chemical Dose × (A/H)1/4 0.15–0.25
Reactive metabolite Dose 1
Stable metabolite Dose × (A/H)1/4 0.15–0.25
PBPKa
Parent chemical Parent AUC 0.01–0.1
Reactive metabolite Tmet/Vt 1–2
Stable metabolite Metabolite AUC 0.02–0.07
Abbreviations: A/H, animal to human body weight ratio; Conc, concentration; PD, pharmacodynamic; PK, pharmacoki-
netic; Tmet/Vt, total metabolite formed in tissue divided by tissue volume.
aBased on physiologically based pharmacokinetic (PBPK) modeling of methylene chloride, trichloroethylene, and vinyl
chloride.the traditional use of body surface area scal-
ing in cancer risk assessment (which resulted
in a factor of about 7 for rats and 13 for
mice) (Table 1). In both cases the concern
that the human might receive a relatively
greater exposure, and hence be at relatively
greater risk, than smaller animals receiving
the same nominal dose reﬂects years of expe-
rience with data on chemical toxicities that,
for the most part, arise from oral exposure to
chemicals that are directly toxic (i.e., as the
parent compound, without the need for
metabolic activation) (3). 
As shown in Table 2, the human is
indeed predicted to be at greater risk for oral
exposures to chemicals that are directly toxic
due to the effect of pharmacokinetic scaling.
For oral exposures to a toxic chemical that
must be cleared by metabolism or urinary
excretion, the internal exposure (AUC) in the
human is greater than in smaller animals at
the same administered dose because the clear-
ance of chemicals, both metabolic and uri-
nary, tends to decrease relative to body weight
as the animal becomes larger (46). In fact, the
allometric scaling of clearance appears to fol-
low body weight raised to the three-quarters
power, producing slightly less of a difference
across species than that predicted by body sur-
face area scaling, which is body weight raised
to the two-thirds power (35). Indeed, based
on a multiagency analysis of the evidence for
cross-species scaling factors, the U.S. EPA
(35) changed from its default body surface
area cross-species scaling for cancer to a new
scaling approach based on body weight raised
to the three-quarters power. 
In both cancer and noncancer risk assess-
ment, there is continuing controversy regard-
ing the appropriate cross-species default for
pharmacodynamics. The origin of the default
scaling/UF actually applied in either case
rests on observations of relationships across
species, which are completely consistent with
pharmacokinetics alone (3). Nevertheless, the
use of pharmacokinetics in a cancer or non-
cancer risk assessment has never been consid-
ered to fully replace the default scaling/UF. It
can be seen from Table 2 that, in the case of
noncancer risk assessment, the default
approach is not necessarily conservative in all
cases, even with the application of the full
animal-to-human UF of 10 (e.g., compare
the human/animal equivalence ratio 0.1 for
the default approach with ratios ranging from
0.01 to 0.1 predicted with pharmacokinetics
for the parent compound AUC). That is, in
some cases, the cross-species differences in
pharmacokinetics alone may exceed the
default factor applied for both pharmacoki-
netics and pharmacodynamics. A similar
result would be obtained for cancer risk
estimates. Particularly in the case of toxicity
due to a stable metabolite, the default
dosimetry and scaling/UF may sometimes
underestimate the human risk (overestimate
the HEC/HED).
Cross-route extrapolation. Another
important use of pharmacokinetics in risk
assessment is for extrapolation from one expo-
sure route to another. In default noncancer
and cancer risk assessment approaches, no
provision is made for the use of toxicity data
from a different route than the human expo-
sure of concern. Thus, for example, in per-
forming an inhalation risk assessment for a
chemical, data from animal studies performed
by the oral route could not be included in the
quantitative dose–response calculations.
Except in the case of exposure–route-speciﬁc
portal-of-entry effects, the use of pharmacoki-
netic modeling makes it possible to combine
data from different routes in a quantitative
risk assessment. Speciﬁcally, the pharmacoki-
netic model can be used to predict the target
tissue dose associated with an animal toxicity
study conducted by one route, and then can
be exercised to predict the equivalent human
exposure by another route that would result
in the same target tissue dose (22).
Dose extrapolation. A third use of phar-
macokinetics in risk assessment is to incor-
porate dose-dependent pharmacokinetics
and metabolism into the dose–response cal-
culations for a chemical. For example, the
observed dose–response relationship between
the exposure concentration and resulting
toxicity of vinyl chloride in animal studies is
highly nonlinear due to the saturation of
metabolism. When a pharmacokinetic
model is used, however, and the tissue dose
is expressed in terms of total metabolism, the
dose response for toxicity becomes linear,
improving the accuracy of dose–response
modeling.
Time extrapolation. In some cases, phar-
macokinetic modeling provides a more accu-
rate method for extrapolating across exposure
time frames than default methods such as the
use of the TWA exposure concentration or
average daily dose. For example, exposure to
100 ppm vinyl chloride for 8 hr will not be
equivalent to exposure to 800 ppm for 1 hr
due to saturation of metabolism at the higher
concentration and rapid postexposure clear-
ance of unmetabolized chemical by exhala-
tion. In the latter exposure, total metabolism
will be signiﬁcantly lower than in the former,
but the AUC for the parent chemical will be
greater. However, for a highly lipophilic
chemical with similar high-afﬁnity, low-capac-
ity metabolism, postexposure metabolism of
chemical stored in fat tissues could result in
nearly the same amount of metabolism from
an exposure of a few hours as from a continu-
ous exposure at the same concentration. In
cases such as these, a pharmacokinetic model,
which incorporates a realistic description of
the dose response for metabolism, is necessary
to determine the correspondence between
exposures over different durations (2,47).
The nature of time extrapolation per-
formed by a pharmacokinetic model will also
be determined to a large extent by the dose
metric selected. For example, the two dose
metrics described for acute toxicity, CMAX
and AUC, respond very differently to
changes in exposure duration. In the case of
inhalation exposure involving a constant con-
centration, the concentrations in the blood
and tissue quickly rise to a steady-state and
then remain constant until the exposure is
terminated, at which time they rapidly return
to zero (except, perhaps, in the fat). Thus
CMAX will be relatively invariant for expo-
sures ranging from tens of minutes to years.
In contrast, for the same exposure scenario,
the AUCs in the tissues will be roughly pro-
portional to the length of exposure. 
It should be recognized, however, that
pharmacokinetic modeling is generally not
very useful for extrapolating across widely
different time frames (e.g., from acute to sub-
chronic or from subchronic to chronic expo-
sure durations). The principal determinants
of the relationship between the effects of
shorter-term and longer-term exposure are,
to a large extent, pharmacodynamic factors
such as fatigue, repair, and compensation.
Therefore, the default approach in noncancer
risk assessment, in which a UF is applied to
account for uncertainty regarding the effect
of significant differences in the duration of
exposure, is still appropriate when pharmaco-
kinetics is considered. For this reason, the
dose metrics calculated with pharmacokinetic
models for noncancer risk assessments of
chemicals are usually calculated as average
daily values, where the average is taken over
the total duration of the exposure. For exam-
ple, instead of calculating the total AUC over
a 90-day exposure, the average daily AUC
(which is equivalent to a daily average con-
centration) is calculated by dividing the total
AUC by the total duration of the exposure in
days (90 in this case). Persistent chemicals
remain in the body long after exposure so the
period of concern for noncancer risk assess-
ment may not be limited to the exposure
period. During this time there can be exten-
sive changes in body composition that alter
distribution and elimination. PBPK models
are well suited for incorporating these aspects
into the risk assessment.
Application of Pharmacokinetic
Modeling in Risk Assessment
As should be apparent from the discussion
thus far, the application of pharmacokinetic
modeling in risk assessment is both chemical-
and end point-specific. Therefore, it is not
possible to completely describe the approach
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cumstances. The application of pharmacoki-
netics in a particular case requires the use of
scientiﬁc judgment and an understanding of
the risk assessment process. Nevertheless, a
number of steps can be described that will
generally be required regardless of the details
of the application. 
Step 1: Selection of potential critical
studies and organization of the mode of
action literature. The ﬁrst step in performing
a risk assessment using pharmacokinetic
modeling is essentially the same as in the
default approach: evaluation of the available
toxicologic and mechanistic data for the
chemical and selection of potential critical
studies. The principal difference is that,
because the cross-species equivalence for dif-
ferent toxicologic end points may vary, as
described above, it is not always possible to
determine from a comparison of the animal
exposure data which study will predict effects
at the lowest human exposures. Another
major difference is the importance of orga-
nizing information regarding the mode of
action of the chemical for the critical end
points. Both qualitative and quantitative data
help determine the appropriate methods
(e.g., choice of dose metric) in later steps.
Step 2: Selection of a pharmacokinetic
model. Once the exposure scenarios and end
points of concern have been selected, the
requirements for a pharmacokinetic model can
be determined. The key elements of this deter-
mination are the animal species and exposure
conditions that the model must be able to
simulate, and the target tissue dose metrics
that the model must be able to calculate. Of
course, it is also necessary to determine
whether the model has been adequately vali-
dated to ensure its reliability for the intended
purpose (14). In particular, the reliability of
the model predictions for each of the dose
metrics should be carefully evaluated (48,49).
Step 3: Calculation of dose metrics for
toxicity studies and analysis of the potential
critical studies. For each study and end point
selected in step 1, the pharmacokinetic
model is used to calculate the appropriate
dose metrics for the end point of concern. In
some cases, it may be possible to postulate
more than one reasonable dose metric. In
such cases, all of the candidate metrics should
be calculated. The final decision regarding
which metric to use should be made only
after the calculations have been completed
for each metric and should consider both the
plausibility and conservatism of the various
options, as will be discussed later. To calcu-
late the dose metrics, the model parameters
are set to those for the species represented in
the study, whether experimental animals or
humans. In the case of developmental stud-
ies, it is necessary to estimate parameters for a
young animal or pregnant female rather than
an average adult. To the extent possible, data
from the study on animal strain, body
weights, age, and activity should be used in
selecting parameters for the model. The
experimental parameters in the model are
then set to reproduce the exposure scenario
performed in the study, and the model is run
for a sufﬁcient period of time to characterize
the animal exposure to the chemical and, if
necessary, its metabolites.
There are often a number of options
regarding the way in which the model
should be run to characterize the exposure.
These depend on the dose metric(s) selected
as appropriate for further analyses based on
the mode of action information. Frequently,
a daily average is estimated, although in
some cases the total over the duration of the
experiment is used. As mentioned earlier,
while the averaging period in the case of can-
cer is typically taken to be the lifetime, the
averaging period in the case of noncancer
risk assessment is considered to be the dura-
tion of the exposure or, perhaps, the critical
window. 
For short-term exposures, the model must
be run for an appropriate period that reﬂects
the dose metric being used and the timing of
the measurement of toxicity in relation to the
period of exposure. For short exposure, this is
easily done by running the model for the total
duration of the exposure (or exposures, for
repeated exposure studies) to obtain dose
metrics. If the animals were held for a postex-
posure period before toxicity was evaluated,
the model must be run either until the end of
the postexposure period or for a sufficient
duration to ensure that the parent chemical
has been completely cleared from the body or,
for a dose metric based on a metabolite, a
long enough time to ensure the complete
clearance of the metabolite. The resulting
dose metric obtained for the total duration of
the exposure (including any postexposure
period) can then be divided by the number of
days over which the experiment was con-
ducted to derive the average daily value. 
The same approach (running the model
for the total duration of the study) can be
used to calculate dose metrics for longer-term
exposures. This approach would typically be
necessary for models that describe changes in
the physiology or chemical handling during
different lifestages (e.g., adolescence, aged).
However, an alternative approach, which is
often attractive for modeling chronic expo-
sures with time-invariant model parameters,
is to estimate the steady-state dose metric.
There are two principal methods for calculat-
ing a steady-state estimate. In the first, the
model is run until steady state is reached; the
dose metric is then calculated by subtraction.
For example, in the case of a chronic oral or
inhalation exposure conducted 5 days/week,
the model can be run consecutively for 1
week, 2 weeks, 3 weeks, and so on. To calcu-
late the average daily AUC for a given week,
the value at the end of the previous week is
subtracted from the value at the end of the
current week and the result is divided by 7.
This process is repeated until the change in
the dose metric from one week to the next is
insigniﬁcant. For continuous exposures, the
comparison can be made on a daily basis
instead of weekly. The other method for esti-
mating the steady-state dose metric is to esti-
mate it from a single day exposure. The
model is run for a single-day exposure plus
an adequate postexposure period to capture
clearance of the parent compound or relevant
metabolite. This value of the single-day dose
metric is then modiﬁed by the necessary fac-
tors to obtain an average daily value (e.g., by
multiplying by ﬁve-sevenths in the case of the
5-day/week exposure). This method, which is
faster but only approximate, is sufficiently
accurate for estimating average daily AUC in
many cases. It can be checked against the ﬁrst
method described to determine its accuracy
in a particular case.
The dose metric calculations needed are
determined by the method to be used for
the noncancer or cancer analysis. If the
NOAEL/UF method is being used in a non-
cancer risk assessment, a dose metric only
needs to be calculated for the NOAEL or
LOAEL exposure for a particular study and
end point. If dose–response modeling is to be
performed, such as in the benchmark dose
approach (50,51), dose metrics must be calcu-
lated for all exposure groups. The dose met-
rics are then used in the dose–response model
in place of the usual exposure concentrations
or administered doses. It is important to
remember that when this is done, the result of
the dose–response modeling will also be in
terms of a value of the dose metric rather than
an exposure concentration or administered
dose. Dose–response modeling is more prop-
erly conducted on the dose metrics because it
is expected that the observed effects of a
chemical will be more simply and directly
related to a measure of target tissue exposure
than to a measure of administered dose. 
Step 4: Application of uncertainty fac-
tors. In the default noncancer risk assessment
approach, animal exposure concentrations
are converted to HECs before any necessary
UFs are applied. In a pharmacokinetic risk
assessment approach, on the other hand, it is
more appropriate to divide the dose metrics
corresponding to the point of departure (for
cancer MOE) or the noncancer equivalents
(e.g., NOAEL or benchmark dose) obtained
from the toxicity studies by the necessary
UFs rather than the HECs or HEDs. The
rationale for applying the UFs to the dose
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rics in dose–response modeling: the observed
effects of a chemical are expected to be more
simply and directly related to a measure of
target tissue exposure than to a measure of
administered dose. The dose metrics are
specifically chosen to provide more useful
measures of the biologically effective dose.
Therefore, it is the dose metrics that should
be adjusted to assure that the biologically
effective dose is reduced to the extent
desired. As a counterexample, consider the
case in which toxicity has been observed for
exposure to a chemical at a concentration
well above the point where saturation of the
metabolism of the chemical occurs and
where the metabolism of the chemical is
responsible for the toxicity. In this case,
applying the UF to a dose metric based on
total metabolism would assure that the
extent of metabolism would be reduced by
the same factor. However, if the concentra-
tion at which the effect was observed were
sufﬁciently higher than the concentration at
which metabolism is saturated, applying the
UF to the exposure concentration might not
actually reduce the extent of metabolism to
any appreciable extent.
The selection of UFs in a pharmacoki-
netic risk assessment is essentially the same as
for the default noncancer process described
earlier, except that the UF for uncertainty in
animal-to-human extrapolation should be
reduced to reﬂect the use of pharmacokinetic
modeling. By analogy to the U.S. EPA (35)
approach for inhalation dosimetry, reduction
of the default animal-to-human UF from 10
to 3 would seem to be reasonable for both
inhalation and oral risk assessments. The
remaining factor of 3 is then considered to
represent uncertainty regarding pharmacody-
namic differences across species and could be
modiﬁed on the basis of other information for
the chemical. The UFs will generally vary
from one study to another, as well as from
one end point to another, as dictated by the
nature of the study (e.g., if only a LOAEL was
identified) and the information associated
with the end point (e.g., if there is evidence
regarding the relative sensitivity of humans
compared to the experimental species).
Step 5: Determination of human expo-
sure. To convert a dose metric to an expo-
sure concentration or administered dose, the
pharmacokinetic model must be “run back-
ward”; that is, the model must be run
repeatedly, varying the exposure concentra-
tion or administered dose until the desired
dose metric value is obtained. In the case of
calculating the acceptable human exposure
corresponding to a given toxicity study, the
physiological, biochemical, and exposure
parameters in the model are set to appropri-
ate human values and the model is iterated
until the dose metric obtained for the
human exposure of concern, often continu-
ous or daily lifetime exposure, is equal to the
dose metric obtained for the toxicity study
divided by the UFs. The dose metric should
be calculated in an analogous way to the
dose metric for the toxicity study; that is, if
the dose metric in the toxicity study was
expressed in terms of an average daily value,
the dose metric used for calculating the asso-
ciated human exposure should also represent
an average daily value. For short-term expo-
sures, where the model has been run for the
total duration of the toxicity study and the
total dose metric value has been calculated,
the dose metric used for calculating the asso-
ciated human exposure should usually be
obtained for an exposure over the same time
period. An exception to this rule is the case
where it is anticipated that the short-term
exposure of concern for the human may rep-
resent a short-term excursion against a back-
ground of chronic exposure. In this case, a
more conservative approach may be pre-
ferred, in which a steady-state dose metric
calculation is used for the human. 
When a steady-state dose metric is used in
both an experimental animal and in a human,
the calculation of a steady-state dose metric in
the human generally requires running the
model for a much longer period of time than
in the animal. In fact, the time required to
reach steady-state in the human can be esti-
mated by multiplying the time to steady state
in the animal by the ratio of human to animal
body weights raised to the one-quarter power.
This concept of the allometric scaling of
equivalent times is sometimes referred to as
“physiological time” (35,52). 
Step 6: Selection of preferred dose met-
ric/study/end point. After calculations for
potential dose–response values (i.e., RfD,
RfC, cancer factors) have been performed
for each of the candidate studies and end
points, the most appropriate alternatives
must be selected. There are two principal
criteria for this selection: plausibility and
conservatism. For each end point, priority
should be given to the dose metric that, on
the basis of the available evidence, appears to
provide the most plausible basis for estimat-
ing the biologically effective dose. The plau-
sibility of a given dose metric is determined
primarily by two factors: its consistency with
available information on the mode of action
(mechanism of toxicity) and the consistency
of its dose response with that of the end
point of concern. The first factor was dis-
cussed above; the second refers both to eval-
uating the dose metric’s ability to linearize
the dose response for the associated end
point within a study (internal consistency)
and its ability to demonstrate a consistent
quantitative relationship of dose metrics for
positive versus negative exposures, regardless
of differences in exposure scenario, route,
and species (external consistency). 
The dose metric used in the pharmaco-
kinetic cancer risk assessment for vinyl chlo-
ride (12) demonstrated all of the attributes
of an effective dose metric. First, the form
of the metric (total daily metabolism
divided by the volume of the liver) was con-
sistent with the mode of action for the end
point of concern (liver tumors), which
involves DNA adduct formation by a highly
reactive chloroethylene epoxide produced
from the metabolism of vinyl chloride.
Second, although the dose response for liver
tumors versus exposure concentration of
vinyl chloride is highly nonlinear with a
plateau at several hundred parts per million,
the dose response for liver tumors versus the
metabolized-dose metric is essentially linear
from 1 ppm to 6,000 ppm. Finally, and
most impressively, when the potency of
vinyl chloride liver carcinogenicity was
expressed in terms of the metabolized-dose
metric, essentially the same potency was cal-
culated from both inhalation and oral stud-
ies in the mouse and rat, as well as from
occupational inhalation exposures in the
human. Although it is rare to find a case
where there is such consistency across
widely diverse studies, a dose metric that
adequately represents the biologically effec-
tive dose should generally have lower values
under exposure conditions with no effect
and higher values for toxic exposures,
regardless of differences in exposure sce-
nario, route, or species.
The other criterion for the selection of the
appropriate dose metric is conservatism.
Where there is an inadequate basis for giving
priority to one dose metric over another, the
most conservative (the dose metric producing
the highest risk or lowest acceptable exposure)
would be used in order to be health protec-
tive. After selecting the most appropriate dose
metric for each end point, the results across
the various studies and end points should be
evaluated using the same criteria—plausibility
(i.e., internal and external consistency of dose-
response) and conservatism—to arrive at the
final recommendation. When a risk assess-
ment is based on an end point in an animal
experiment, it may sometimes be possible to
evaluate data from human exposures as a test
of the plausibility of the result, even though
the data might not be adequate to serve as
the basis for calculating an alternative value.
Another useful exercise is to vary the physio-
logical and biochemical parameters used in
the model to determine the effect of human
pharmacokinetic variability on the dose met-
ric (53). In particular, the model can be used
to evaluate whether selected groups may
represent sensitive subpopulations (e.g.,
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due to differences in exposure or pharmaco-
kinetic factors.
Discussion
We have outlined a process for consistently
using dosimetry information in a mode of
action-based dose–response analysis. The ﬁrst
step is the evaluation of potential critical stud-
ies and the relevant mode of action informa-
tion for the effect observed in the critical
studies. Because the appropriate dose metric is
selected based on the mode of action, differ-
ent critical effects (i.e., effects that might form
the basis for estimating acceptable exposures)
may require different dose metrics. A PBPK
model appropriately parameterized for the
species in which the critical effects were
observed is then selected (Step 2) and used to
calculate the relevant dose metrics for the
benchmark dose or NOAEL of the critical
effects (Step 3). Uncertainty factors are then
selected and applied to the dose metric
description of the point of departure (Step 4).
Next, a human parameterized model is used
to estimate the exposure concentration that
would produce the same value for the dose
metric as that obtained from the animal study
modiﬁed by the uncertainty factors (Step 5).
Finally, the values obtained for the different
studies are compared and used as appropriate
for the purpose of regulation or analysis under
consideration (Step 6). Generally, the study
giving the lowest allowable exposure would be
used for establishing acceptable exposure lev-
els assuming lifetime daily exposure. If you
were evaluating the potential for a speciﬁc tar-
get organ toxicity to occur due to a mixture of
chemicals, you would select the value based
on the critical study with that end point. 
Many of the issues described in this paper
with regard to the PBPK-based approach are
equally applicable to the default risk assess-
ment process. For example, the selection of a
dose metric that is appropriate for the chemi-
cal and toxicity of concern, while more evi-
dent in the PBPK-based approach, is just as
important in the default approach. A case in
point is the question of whether concentra-
tion or AUC should be used for short-term
exposure guidelines (28). Unfortunately, with
the exception of the RfC dosimetry guidelines
(42), the selection of dose metric is typically
described more as a matter of policy than of
scientiﬁc judgment. In this regard, the spirit
of the recently proposed cancer guidelines
(44) represents an important departure from
previous guidelines, which identiﬁed defaults
as policy positions and required substantial
justification for departure from the default
approach. In contrast, defaults under the new
cancer guidelines are described as no-informa-
tion alternatives, the use of which must be
defended on the basis of the lack of chemical-
speciﬁc information to support a more scien-
tiﬁcally appropriate approach.
The analyses described in this paper have
focused on the use of pharmacokinetics with
empirical analyses of the dose response for
the effect. This reﬂects the greater extent of
our knowledge about pharmacokinetics and
its modeling as opposed to our knowledge of
toxicity and pharmacodynamic modeling.
However, as pharmacodynamic models
become available, they can be readily incor-
porated into the process described here.
Pharmacodynamic models currently often
only exist for the animal species in the toxic-
ity study and human parameters values, or
the appropriateness of the model structure
for humans may be unknown. Under these
circumstances, the model would be used
much as the empirical models are used for
benchmark dose analysis (Step 3). That is,
the pharmacodynamic model would be used
to better describe or predict the dose
response in the animal study to obtain the
point of departure for the subsequent analy-
ses. At this time, this approach has largely
been explored in the area of cancer analysis
using clonal growth models (54,55).
The goal of research in pharmacodynamic
modeling is to develop models that, like phar-
macokinetic models, can be parameterized for
both animals and humans. After meeting this
goal, the chemical risk assessment process
would be very similar to that described in this
paper, except that both a pharmacokinetic
and a pharmacodynamic model would be
used to analyze the animal study (Step 3) and
then human versions of both models would
be used to determine the human exposure
that would be protective of that effect occur-
ring in humans (Step 5). As noted earlier for
pharmacokinetic analyses, this use of pharma-
codynamic modeling would represent a sig-
nificant change in the issue of cross-species
concordance. Biologically based analyses
assume some degree of concordance in the
mechanism of action, if not in the resulting
toxicity. The current default position is that
end points will be used with no assumption of
concordance unless it is conclusively demon-
strated to be an animal-speciﬁc mechanism.
Although this may be a health protective posi-
tion, as it stands, it is impossible to use mech-
anistic toxicology or modeling in risk
assessment and impossible to improve our
ability to predict human consequences based
upon animal studies.
There is a continuing interest on the part
of regulatory agencies concerning the use of
PBPK modeling in chemical risk assessment.
Although risk assessments using PBPK mod-
els have been proposed for a number of chem-
icals, for both cancer and noncancer end
points, there are relatively few cases to date of
the actual acceptance of PBPK-based risk
assessments by agencies. The slow progress of
the application of PBPK modeling in risk
assessment may be due in part to the lack of a
common expectation regarding the necessary
elements of a PBPK-based approach. Our
intent in this paper was to describe the essen-
tial elements of a preferred approach for
applying PBPK modeling in a chemical risk
assessment, whether for cancer or noncancer
end points. We hope that, to the extent that
PBPK-based risk assessments can adhere to a
similar protocol, agencies will become familiar
with the process and will begin to accept it. 
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where TD is toxic dose (milligrams), A is
animal (e.g., rat or mouse), BW is body
weight (kilograms), H is human; a is a con-
stant, and b is a scaling exponent (e.g., 2/3
or 3/4).
By substituting a =  TDA/BWA
b
(rearranged Equation 2) into Equation 3,
the conversion of the animal dose
expressed in milligrams to the human dose
in the same units is obtained:
[4]
To obtain the relationship in the mil-
ligrams per kilogram units more typically
reported in toxicology:
[5]
This equation is rearranged for animals: 
[6]
Substituting Equation 6 into Equation 5
(for humans) obtains the conversion of the
animal dose expressed in milligrams per
kilogram to the human dose in the same
units:
[7]
Equivalently the equation may be written as
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